
Padcev With or Without Keytruda Elicits Responses in Urothelial Cancer
Among patients with metastatic urothelial carcinoma — a form of bladder cancer — treatment with Padcev (enfortumab vedotin) plus Keytruda (pembrolizumab) was found to elicit responses in the first-line setting, while Padcev showed clinical benefit in later …